Hoth Therapeutics’ (HOTH) Buy Rating Reiterated at D. Boral Capital

D. Boral Capital restated their buy rating on shares of Hoth Therapeutics (NASDAQ:HOTH) in a report published on Tuesday,Benzinga reports. They currently have a $5.00 target price on the stock.

HOTH has been the topic of several other reports. Benchmark reaffirmed a “speculative buy” rating and issued a $3.00 price target on shares of Hoth Therapeutics in a report on Friday, October 11th. HC Wainwright reaffirmed a “buy” rating and set a $4.00 price target on shares of Hoth Therapeutics in a research report on Monday, November 4th.

Hoth Therapeutics Price Performance

Shares of Hoth Therapeutics stock opened at $2.28 on Tuesday. Hoth Therapeutics has a 1-year low of $0.58 and a 1-year high of $3.80. The company has a market capitalization of $15.74 million, a PE ratio of -1.73 and a beta of 0.75. The business has a 50-day moving average of $0.86 and a 200-day moving average of $0.85.

Hoth Therapeutics (NASDAQ:HOTH) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.31) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.30) by ($0.01). On average, equities analysts expect that Hoth Therapeutics will post -1.18 earnings per share for the current fiscal year.

Institutional Trading of Hoth Therapeutics

An institutional investor recently bought a new position in Hoth Therapeutics stock. Virtu Financial LLC purchased a new position in Hoth Therapeutics, Inc. (NASDAQ:HOTH) during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm purchased 32,636 shares of the company’s stock, valued at approximately $29,000. Virtu Financial LLC owned about 0.47% of Hoth Therapeutics as of its most recent filing with the Securities and Exchange Commission. Institutional investors own 7.08% of the company’s stock.

About Hoth Therapeutics

Hoth Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapies for unmet medical needs. It is involved in the development of HT-001, a topical formulation, which is in Phase II clinical trial for the treatment of patients with rash and skin disorders associated with initial and repeat courses of tyrosine kinase epidermal growth factor receptor inhibitor therapy; HT-KIT to treat mast-cell derived cancers and anaphylaxis; HT-TBI to treat traumatic brain injury and ischemic stroke; HT-ALZ for the treatment and/or prevention of Alzheimer's or other neuroinflammatory diseases; HT-004 for treatment of asthma and allergies using inhalational administration; HT-003 for the treatment of acne and psoriasis, as well as inflammatory bowel diseases; and HT-002, a novel peptide for treating COVID-19.